Domain Registration Corp (“BioPharm Asia, Inc”) Opens 360 New Drugstores in Jilin and Liaoning Provinces

New Stores Expand Customer Reach and Influence in North East China

SHENZHEN, China, June 12 /PRNewswire-Asia/ -- Domain Registration Corp. (OTC Bulletin Board: DOMR), today announces that the Company (in the process of changing its name to “BioPharm Asia Inc.”) has opened 360 new drugstores in Jilin and Liaoning Provinces, through its subsidiary Tonghua Shengantang Medical & Pharmacy Company Limited. A majority of the 360 chain drugstores are strategically located in the following areas: Tonghua, Jilin, Changchun, Siping and Yanji in Jilin Province, as well as Dalian in Liaoning Province.

With the implementation of universal healthcare reforms and the continuous improvement of rural medical services in China, the second-tier and third-tier cities, towns and counties will begin receiving comprehensive medical coverage. Likewise, increases in disposable income throughout the rural population have accelerated the urbanization of these relatively more developed areas. At the same time, widespread chain store retailing is becoming more accepted in the rural markets, and “BioPharm Asia” is poised to take advantage of their increasingly dense population and purchasing power, especially in Jilin and Liaoning Provinces.

“The successful addition of 360 new drugstores constitutes a major step in improving BioPharm Asia’s consumer reach and achieving distribution wide economies of scale,” said Yunlu Yin, Chief Executive Officer. “By continuing to open new drugstores in target distribution markets like Jilin and Liaoning Provinces, BioPharm Asia is aggressively penetrating these pharmaceutical markets and appealing to China’s rising middle class by catering directly to its rural medical needs.”

About Domain Registration Corp (“BioPharm Asia, Inc.”)

In the process of changing its corporate name to “BioPharm Asia, Inc.”, the Company is primarily engaged in the retail sale of medical products in China, complemented by a series of integrated business segments that include the cultivation of Chinese herbal medicines, pharmaceutical production and wholesale medicine distribution. Following several successful acquisitions through China Northern Pharmacy Holding Group Limited, the Company has preliminarily completed the integration of its distribution channels, expanding its trading business (which includes chain stores, distribution and wholesale business) to include pharmaceutical manufacturing and cultivation of medicinal raw materials. For more information, please visit http://www.biopharmasiainc.com .

Forward-looking statement: Except for the historical information, the matters discussed in this news release may contain forward-looking statements, including, but not limited to, factors relating to future sales. These forward-looking statements may involve a number of risks and uncertainties. Actual results may differ materially based on a number of factors, including, but not limited to, uncertainties in product demand, risks related to doing business in China, the impact of competitive products and pricing, changing economic conditions around the world, release and sales of new products and other risk factors detailed in the company’s most recent annual report and other filings with the Securities and Exchange Commission.